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Aortic stenosis (AS) is more commonly caused by calcification of a congenitally bicuspid or trileaflet valve. The prevalence of AS increases with age, averaging 0.2% in the 50-to 59-year cohort and increasing to 9.8% in the 80-to 89-year cohort. 1 Because of low efficacy of medical therapy, annually worldwide 27 000 patients become eligible for transcatheter aortic valve replacement (TAVR) and 67 500 for surgical aortic valve replacement (AVR), 1 according current guidelines. Transthyretin (TTR) amyloidosis (ATTR) is a fatal disorder that is characterized primarily by progressive neuropathy and cardiomyopathy. It occurs either as a mutant form (with autosomal dominant inheritance) or as a more frequent wild-type form (with predominant cardiac involvement). 3 TTR, that is synthesized by the liver, has a physiological function of transporting thyroxin and retinol-binding proteins; it has a crucial role in behaviour, cognition, nerve regeneration, and axonal growth. More than 80 single point mutations can increase the likelihood of TTR to aggregate into insoluble amyloid fibres. Deposition of amyloid in the myocardial wall causes diastolic dysfunction, restrictive physiology with late loss of systolic function, arrhythmias, and heart failure. 3 ATTR-cardiac amyloidosis (CA) has a male preponderance and was formerly known as 'senile amyloidosis', reflecting its first appearance beyond 60-70 years of age and prevalence at autopsy of up to 25% among octogenarians. 4 Because of ageing of the population, the association between severe AS and ATTR-CA is more frequent than thought, as suggested by small previous studies, assessing invasively the presence of cardiac TTR deposition in elderly patients with severe symptomatic AS. 5, 6 Management of AS and ATTR-CA patients is challenging. Improvement of survival and symptoms after AVR may be limited due to high risk of operative and post-operative complications with surgical AVR 7 and TAVR, 8 and poor prognosis of patients with ATTR-CA. 9 Thus, diagnostic work-up of ATTR-CA should be performed in selected patients with severe AS candidate for AVR before referral to the procedure. Some retrospective studies 5, 6 demonstrated invasively a prevalence of 6-12% of ATTR-CA in severe AS. In this issue of the journal, Castaño et al. 10 reported the results of their prospective study investigating the prevalence and phenotype of ATTR-CA in 151 elderly patients (> _65 years) with severe symptomatic AS undergoing TAVR. Enrolled patients underwent transthoracic echocardiography with speckle strain imaging at the time of TAVR work-up and 99m Technetium (Tc)-pyrophosphate (PYP) scanning within 30 days after TAVR. In addition, the authors assessed the association of several parameters with ATTR-CA using multivariable logistic regression and built receiver operating curves to evaluate the best predictors of ATTR-CA in severe symptomatic AS. From a methodological point of view, at variance with other studies 5, 6 exploring the prevalence of ATTR-CA in AS, the authors did not perform cardiac biopsy to confirm diagnosis. Although endomyocardial biopsy and tissue typing with histological staining and precursor protein confirmation using mass spectrometry remain the gold standard for diagnosis of ATTR-CA, 11 as acknowledged by the authors, these procedures may not be appropriate in frail elderly patients, in particular those scheduled for TAVR and not for surgical AVR. Yet, positive 99mTc-PYP scan in association with a normal electrophoretic protein pattern shows specificity of 100% for ATTR-CA, replacing the need for cardiac biopsy.
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Furthermore, this strategy may be useful to not delay diagnosis in patients eligible for TAVR. Key findings of this study are the relatively high prevalence (16%; n = 24) of ATTR-CA in severe AS and the association with a severe AS D2 phenotype of low-flow low-gradient with mildly reduced ejection fraction. The authors also studied echocardiographic features of ATTR-CA in AS patients. In comparison with TAVR patients without ATTR-CA, ATTR-CA patients had a thicker septum, higher left ventricular mass index, lower stroke volume index, more advanced grade of diastolic dysfunction, and more impaired global longitudinal strain. Interestingly, at variance with ATTR-CA without AS, apex longitudinal strain was impaired, probably due to raised parietal stress and increased afterload induced by AS that masks reduced apical deposition of amyloid in comparison with other segments. In addition, average mitral annular S' was the best predictor of ATTR-CA in multivariable logistic regression, and a cut-off value of S' <6 conferred 100% sensitivity to predict a positive 99mTc-PYP amyloid scan. The clinical relevance of these results relies on the demonstration that echocardiography with speckle strain imaging may be an accurate, low-cost, widely available screening method to identify, in a high risk, older population with severe calcific AS, patients with a high probability of concomitant ATTR-CA, assessed noninvasively by 99mTc-PYP scintigraphy.
Thus, the study of Castaño et al. focuses on a clinically relevant condition, suggesting a new potential strategy to screen non-invasively for the presence of ATTR-CA. An important question raised is whether there is a causative link between AS and ATTR-CA. AS is the end result of an inflammatory process caused by endothelial damage due to mechanical stress, lipid penetration leading to fibrosis, leaflet thickening, and calcification. 1, 12 In fact, there is accumulating evidence for a pivotal role for oxidative stress, inflammation, and extracellular remodelling in the TTR amyloidogenic process. 13 Furthermore, AS increases cardiac pressure overload that could have deleterious effects on myocardial remodelling in ATTR-CA, worsening prognosis, whereas amyloid infiltration leads to deleterious effects on diastolic and systolic function in AS, complicating the clinical course. 14 Although it is not clear whether AS and ATTR-CA share a common physiopathogenetic mechanism or whether their frequent co-existence in older populations induces only a more severe clinical outcome of each disease, echocardiographic assessment of systolic and diastolic function and strain imaging parameters, as proposed by Castaño et al., 10 provide a valid strategy to select patients to refer to 99mTc-PYP amyloid scan before TAVR. Yet, prospective follow-up studies to assess the impact of ATTR-CA on outcome of patients with AS are strongly needed to assess thoroughly the impact of this strategy on the clinical course of patients with ATTRCA and AS.
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